Plus Therapeutics (NASDAQ:CNSY) Raised to “Hold” at Zacks Research

Plus Therapeutics (NASDAQ:CNSY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Separately, Weiss Ratings began coverage on Plus Therapeutics in a research note on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Plus Therapeutics Price Performance

CNSY stock opened at $2.94 on Tuesday. The stock has a market capitalization of $22.31 million, a PE ratio of -0.88 and a beta of 1.39. Plus Therapeutics has a 1-year low of $2.62 and a 1-year high of $23.42.

Plus Therapeutics (NASDAQ:CNSY) last announced its earnings results on Friday, August 14th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.35). Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. Analysts expect that Plus Therapeutics will post -3.76 earnings per share for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.